Phase II Study of AP0302 5% Versus a Vehicle Comparator
Phase II Study of AP0302 5% Versus a Vehicle Comparator
This study is designed to evaluate the analgesic safety and efficacy of study drug (AP0302)
 applied topically every 6 hours as compared to a vehicle, in subjects experiencing delayed
 onset muscle soreness.
The purpose of this study is to evaluate the efficacy and safety of S-Ibuprofen Topical Gel
 5% in reducing pain/soreness associated with delayed onset muscle soreness (DOMS).
Inclusion Criteria:

 -  no clinically significant medical conditions

 -  BMI between 18-30

 -  negative drug, alcohol, pregnancy screens

 -  other protocol-defined inclusion criteria may apply

 Exclusion Criteria:

 -  no upper extremity workout in last 6 months

 -  no job requiring heavy lifting

 -  history of muscle disorders

 -  allergy or intolerance to study drug

 -  history of recent pain medication use

 -  other protocol-defined exclusion criteria may apply